; and (2) brief the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives on— (A) interim results from the studies described in paragraph (1); and (B) any barriers that may prevent adequate and timely enrollment of patients in any new clinical study described in paragraph (1). (b) Study on medication treatments for opioid use disorders The Secretary of Health and Human Services, acting through the Assistant Secretary for Mental Health and Substance Use, shall— (1) study— (A) the early impact on access to medication treatment for opioid use disorder and opioid-related overdose deaths through buprenorphine prescribing pursuant to section 303(g) of the Controlled Substances Act ( 21 U.S.C. 823(g) ), as amended by section 1262 of title I of division FF of the Mental Health and Well-Being Act of 2022; (B) the prevalence of patients with opioid use disorder, in each Substate region, as defined by the National Survey on Drug Use and Health of the Substance Abuse and Mental Health Services Administration; and (C) a survey of retail pharmacies nationwide, disaggregated by State, to determine which pharmacies serve as methadone dispensing units for opioid treatment programs; and (2) submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives— (A) not later than 3 years after the date of enactment of this Act, an initial report on the study under paragraph (1); and (B) not later than 4 years after the date of enactment of this Act, a final report on the study under paragraph (1). 210. FASD Respect Act (a) In general Part O of title III of the Public Health Service Act ( 42 U.S.C. 280f et seq. ) is amended— (1) by amending the part heading to read as follows: Fetal alcohol spectrum disorders prevention and services program